STEVENSON, Md., Sept. 19, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Foundation Medicine, Inc. (Nasdaq:FMI) (“Foundation” or the “Company”) securities during the period between February 26, 2014 and November 3, 2015, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until September 26, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Foundation securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that issues with the reimbursement process and coverage for Foundation’s tumor tests by Medicare would affect the Company’s financial guidance.
According to the complaint, following a July 29, 2015 announcement that the Company was not making the strides obtaining coverage it had claimed to have been making during the Class Period and the financial guidance would be revised, and a November 3, 2015 announcement regarding a further revision to the already reduced number of clinical tests it expected to report, the value of Foundation shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Foundation securities purchased on or after February 26, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


FDA Approves Mitapivat for Anemia in Thalassemia Patients
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



